Discontinuation of any antihypertensive therapy in the incident user cohort
| Initial drug class | No. (%) | Crude subdistribution hazard ratio (95% CI) | Adjusted subdistribution hazard ratio (95% CI)* | ||
|---|---|---|---|---|---|
| Discontinued | Died | Censored | |||
| Thiazide monotherapy n = 86 008 | 55 728 (64.8) | 999 (1.2) | 29 281 (34.0) | Ref. | Ref. |
| ACE inhibitor monotherapy n = 100 670 | 61 838 (61.4) | 1337 (1.3) | 37 495 (37.2) | 0.96 (0.95–0.97) | 0.96 (0.95–0.97) |
| ARB monotherapy n = 11 449 | 7423 (64.8) | 95 (0.8) | 3931 (34.3) | 1.07 (1.04–1.09) | 0.84 (0.81–0.87) |
| Thiazide with ACE inhibitor or ARB n = 18 909 | 11 525 (60.9) | 243 (1.3) | 7141 (37.8) | 0.96 (0.94–0.98) | 0.86 (0.84–0.88) |
| CCB n = 15 745 | 10 085 (64.1) | 198 (1.3) | 5462 (34.7) | 1.08 (1.06–1.10) | 1.04 (1.02–1.07) |
Note: ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blocker, CCB = calcium channel blocker, CI = confidence interval, Ref. = reference category.
↵* Adjusted for age, sex, income level, provincial drug coverage and geographical area.